CSBR (Champions Oncology) EBIT : $-3.04 Mil (TTM As of Jul. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology EBIT?

Champions Oncology's earnings before interest and taxes (EBIT) for the three months ended in Jul. 2024 was $1.33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jul. 2024 was $-3.04 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Champions Oncology's annualized ROC % for the quarter that ended in Jul. 2024 was 21.07%. Champions Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was 45.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Champions Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -4.05%.

Champions Oncology EBIT Historical Data

The historical data trend for Champions Oncology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology EBIT Chart

Champions Oncology Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

EBIT

Get a 7-Day Free Trial

-1.59

0.37

0.61

-4.45

-6.92

Champions Oncology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
EBIT	Get a 7-Day Free Trial															-2.55	-1.96	-2.58	0.16	1.33

Competitive Comparison of Champions Oncology's EBIT

For the Biotechnology subindustry, Champions Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Champions Oncology's EV-to-EBIT falls into.

Champions Oncology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04 Mil.

Champions Oncology (NAS:CSBR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Champions Oncology's annualized ROC % for the quarter that ended in Jul. 2024 is calculated as:

	ROC % (Q: Jul. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Apr. 2024 )	+	Invested Capital (Q: Jul. 2024 ))	/ count )
=	5.316 * ( 1 - 1.57% )	/	( (26.074	+	23.587)	/ 2 )
=	5.2325388	/	24.8305
=	21.07 %

where

	Invested Capital		(Q: Apr. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	26.132	-	7.96	-	( 2.618	-	max(0, 21.541	-	13.639	+	2.618	))
=	26.074

	Invested Capital		(Q: Jul. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.933	-	7.332	-	( 2.892	-	max(0, 19.164	-	13.178	+	2.892	))
=	23.587

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Champions Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jul. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Apr. 2024		Q: Jul. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	5.316	/	( ( (11.973 + max(-13.823, 0))	+	(11.235 + max(-11.819, 0)) )	/	2 )
=	5.316	/	( ( 11.973	+	11.235 )	/	2 )
=	5.316	/	11.604
=	45.81 %

where Working Capital is:

	Working Capital		(Q: Apr. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.886	+	0	+	1.495)	-	(7.96	+	12.094	+	0.15)
=	-13.823

	Working Capital		(Q: Jul. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.722	+	0	+	1.254)	-	(7.332	+	10.312	+	0.151)
=	-11.819

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Champions Oncology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jul. 2024 )
	=	-3.039	/	75.039
	=	-4.05 %

Champions Oncology EBIT Related Terms

Thank you for viewing the detailed overview of Champions Oncology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Executives

Daniel Newman Mendelson	director	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris	director, officer: President	855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld	director	ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp.	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman	director, officer: Chief Executive Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins	10 percent owner
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Harry R Weller	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815